Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04039230 |
|
Recruitment Status :
Recruiting
First Posted : July 31, 2019
Last Update Posted : April 1, 2024
|
Sponsor:
Massachusetts General Hospital
Collaborator:
Pfizer
Information provided by (Responsible Party):
Laura M. Spring, MD, Massachusetts General Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2025 |
| Estimated Study Completion Date : | December 2026 |